Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM). Issue 13 (6th April 2022)

• Record Type: Journal Article
• Authors: Amadeo, Brice; Penel, Nicolas; Coindre, Jean‐Michel; Ray‐Coquard, Isabelle; Plouvier, Sandrine; Delafosse, Patricia; Bouvier, Anne‐Marie; Gallet, Justine; Lacourt, Aude; Galvin, Angéline; Coureau, Gaëlle; Monnereau, Alain; Blay, Jean‐Yves; Desandes, Emmanuel; Mathoulin‐Pélissier, Simone
• Is Part Of: Cancer. Volume 128:Issue 13(2022)
• Page Start: 2483
• Page End: 2492
• Publication Date: 2022-04-06
• Subjects: cancer registry -- France -- French Network of Cancer Registries (FRANCIM network) -- sarcoma -- survival; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.34217
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: Sarcomas are rare, heterogeneous, ubiquitously localized malignancies with many histologic subtypes and genomic patterns. The survival of patients with sarcoma has rarely been described based on this heterogeneity; therefore, the authors' objective was to estimate survival outcomes in patients who had sarcomas using the 2020 version of the World Health Organization classification of soft tissue and bone tumors. METHODS: Patients older than 15 years who had incident sarcoma diagnosed between 2005 and 2010 were extracted from 14 French population‐based cancer registries covering 18% of the French metropolitan population. Vital status for each patient was actively followed up to June 30, 2013. Net survival (NS) was estimated using the unbiased Pohar‐Perme method. RESULTS: Overall, 4202 patients were included. NS declined with increasing age at diagnosis. According to topographic groups, large 5‐year NS disparities were observed, ranging from 47% among women with gynecologic sarcomas to 89% among patients with skin sarcomas. Patients with soft tissue, bone, and gastrointestinal sarcomas had 5‐year NS rates of 53%, 61%, and 70%, respectively. Similar heterogeneity was observed according to histologic subtypes, with 5‐year NS ranging from 19% for patients with angiosarcomas to 96% for patients with dermatofibrosarcomas. Patients with sarcoma who displayed missense mutations had a better 5‐year NS (74%); those with MDM2 ‐amplified sarcomas had the worst NS (45%). CONCLUSIONS: NS rates in patients with sarcoma are presented here for the first time based on the 2020 World Health Organization classification applied to population‐based registry data. Large prognostic heterogeneity was observed based on age, topographic and histologic groups, and genomic alteration profiles, constituting a benchmark for future studies and clinical trials. Abstract : In this study based on the 2020 version of the World Health Organization classification of soft tissue and bone tumors applied to the French population‐based cancer registries, large survival heterogeneity of sarcomas was observed on age, topographic and histologic groups, and genomic alteration profiles. This study emphasized the major determinants of survival in patients with sarcoma, providing a new benchmark for future studies or clinical trials.